FY2016 Earnings Estimate for Viveve Medical Inc (VIVE) Issued By Zacks Investment Research
Viveve Medical Inc (NASDAQ:VIVE) – Analysts at Zacks Investment Research cut their FY2016 earnings per share (EPS) estimates for shares of Viveve Medical in a research note issued on Wednesday. Zacks Investment Research analyst B. Marckx now expects that the brokerage will post earnings per share of ($2.08) for the year, down from their previous forecast of ($1.94). Zacks Investment Research also issued estimates for Viveve Medical’s Q4 2016 earnings at ($0.46) EPS, FY2017 earnings at ($1.46) EPS, FY2018 earnings at ($1.10) EPS and FY2019 earnings at ($0.96) EPS.
Viveve Medical (NASDAQ:VIVE) last posted its earnings results on Thursday, November 10th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. The company earned $1.85 million during the quarter, compared to the consensus estimate of $1.70 million.
Several other brokerages have also weighed in on VIVE. Ladenburg Thalmann began coverage on Viveve Medical in a report on Tuesday, September 20th. They issued a “buy” rating and a $22.00 price objective for the company. B. Riley reissued a “buy” rating and issued a $8.00 price objective on shares of Viveve Medical in a report on Friday.
Viveve Medical (NASDAQ:VIVE) opened at 6.64 on Monday. The stock has a 50 day moving average of $6.09 and a 200-day moving average of $6.40. Viveve Medical has a 12-month low of $4.02 and a 12-month high of $10.50.
An institutional investor recently raised its position in Viveve Medical stock. RTW Investments LLC raised its position in shares of Viveve Medical Inc (NASDAQ:VIVE) by 3.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 839,274 shares of the company’s stock after buying an additional 24,328 shares during the period. Viveve Medical accounts for 1.5% of RTW Investments LLC’s holdings, making the stock its 15th largest position. RTW Investments LLC’s holdings in Viveve Medical were worth $6,060,000 as of its most recent filing with the SEC.
About Viveve Medical
Viveve Medical, Inc, formerly PLC Systems, Inc, designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office.
Receive News & Stock Ratings for Viveve Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc and related stocks with our FREE daily email newsletter.